B of A Securities Maintains Buy on Biomarin Pharmaceutical, Lowers Price Target to $185
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Geoff Meacham maintains a Buy rating on Biomarin Pharmaceutical (NASDAQ:BMRN) but lowers the price target from $200 to $185.
July 21, 2023 | 4:51 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Biomarin Pharmaceutical's price target has been lowered from $200 to $185 by B of A Securities, though the Buy rating is maintained.
The news is directly about Biomarin Pharmaceutical. The lowering of the price target might cause some short-term negative sentiment among investors, but the maintained Buy rating indicates that the analyst still sees upside potential in the stock. Therefore, the short-term impact on the stock price is neutral.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100